Udvalget fandt, at fordelene ved IVEMEND opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for IVEMEND.
The Committee decided that IVEMEND’ s benefits are greater than its risks and recommended that IVEMEND be given marketing authorisation.